These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 12908508)

  • 21. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine.
    Van Damme P; Van Herck K
    Expert Rev Vaccines; 2004 Jun; 3(3):249-67. PubMed ID: 15176942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix®) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen®) for Japanese travelers to endemic countries.
    Fukushima S; Kiyohara T; Ishii K; Nakano T; Hamada A
    Vaccine; 2017 Nov; 35(47):6412-6415. PubMed ID: 29029942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.
    Deneke MG; Arguedas MR
    Expert Rev Vaccines; 2003 Oct; 2(5):661-72. PubMed ID: 14711327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of an inactivated hepatitis A pediatric vaccine: three-year post-booster follow-up.
    Dagan R; Greenberg D; Weber F
    Vaccine; 2005 Oct; 23(44):5144-8. PubMed ID: 16043271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.
    Keystone JS; Hershey JH
    Int J Infect Dis; 2008 Jan; 12(1):3-11. PubMed ID: 17643334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative study of the reactivity, safety and immunogenicity of "Havrix" inactivated hepatitis A vaccine].
    Noskova AV; Gorbunov MA; Pavlova LI; El'shina GA; Sharipova IS; Karpovich LG; Kalashnikova TI; Bektimirov TA; Rikhmer VV; El'nikov VS
    Vopr Virusol; 2000; 45(6):42-4. PubMed ID: 11200647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined hepatitis A and B vaccine: providing a bright future for preventing hepatitis.
    Hewlett AT
    Expert Opin Biol Ther; 2009 Sep; 9(9):1235-40. PubMed ID: 19601727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China.
    Zhuang GH; Pan XJ; Wang XL
    Vaccine; 2008 Aug; 26(35):4608-16. PubMed ID: 18597903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)].
    Xu Z; Wang X; Li R; Meng Z; Zhang Y; Gong J; Ma J; Li Y; Zhao S; Li Y; Zhao Y; Huang Q; Luo D; Xia J; Liu H; Liu X; Ouyang P
    Zhonghua Yi Xue Za Zhi; 2002 May; 82(10):678-81. PubMed ID: 12133465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine.
    Beran J
    Expert Rev Vaccines; 2007 Dec; 6(6):891-902. PubMed ID: 18377352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
    Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
    J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunization against Hepatitis A.
    Shouval D
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29661808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical inquiries: Who should get hepatitis A vaccination?
    Brown R; Cable K; Sams R
    J Fam Pract; 2005 Jul; 54(7):624-5; discussion 624. PubMed ID: 16009092
    [No Abstract]   [Full Text] [Related]  

  • 37. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine.
    Iwarson S; Lindh M; Widerström L
    J Travel Med; 2004; 11(2):120-1. PubMed ID: 15109480
    [No Abstract]   [Full Text] [Related]  

  • 38. [The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine].
    Zheng H; Cui FQ
    Zhongguo Yi Miao He Mian Yi; 2009 Aug; 15(4):371-4. PubMed ID: 20077742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis A vaccination of Argentinean infants: comparison of two vaccination schedules.
    López EL; Contrini MM; Xifró MC; Cattaneo MA; Zambrano B; Dumas R; Rouyrre N; Weber F
    Vaccine; 2007 Jan; 25(1):102-8. PubMed ID: 16914234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis A and B booster recommendations: implications for travelers.
    Zuckerman JN; Connor BA; von Sonnenburg F
    Clin Infect Dis; 2005 Oct; 41(7):1020-6. PubMed ID: 16142669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.